Herach Yadegarian, MD
General Practice · Glendale, CANPI 1124188628
Payments from drug & device makers
Across 179 payments — averaging $21.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$583
- AbbVie$437
- Ardelyx, Inc.$336
- AstraZeneca$285
- Astellas Pharma US Inc$210
- Lundbeck LLC$180
- plus $2K from 29 others
What the payments were for
- Food & beverage$3,80197%
- Education$993%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 28 | $583 |
| AbbVie(2 entities) | 21 | $437 |
| Ardelyx, Inc. | 11 | $336 |
| AstraZeneca | 17 | $285 |
| Astellas Pharma US Inc | 8 | $210 |
| Lundbeck LLC | 7 | $180 |
| Lilly USA, LLC | 7 | $177 |
| Almatica Pharma LLC | 8 | $170 |
| Boehringer Ingelheim | 6 | $156 |
| Sanofi-aventis U.S. LLC | 8 | $152 |
| Kowa Pharmaceuticals America, Inc. | 6 | $136 |
| Otsuka America Pharmaceutical, Inc. | 5 | $120 |
| GSK | 4 | $94 |
| Ironwood Pharmaceuticals, Inc | 4 | $89 |
| Pfizer | 5 | $88 |
| Amarin Pharma, Inc. | 4 | $76 |
| Novo Nordisk | 4 | $65 |
| Merck | 3 | $60 |
| Alk-abello, Inc | 2 | $56 |
| Arbor Pharmaceuticals, Inc. | 3 | $49 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $49 |
| Bayer | 2 | $42 |
| Pulmonx Corporation | 1 | $29 |
| Cranial Technologies, Inc | 2 | $29 |
| Shield Therapeutics Inc | 1 | $29 |
| Aimmune Therapeutics, Inc. | 1 | $27 |
| Optinose US, Inc. | 1 | $25 |
| Esperion Therapeutics, Inc. | 1 | $25 |
| Abbott | 1 | $22 |
| Phathom Pharmaceuticals, Inc. | 1 | $22 |
| Kaleo, Inc. | 1 | $20 |
| Scilex Pharmaceuticals Inc. | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Sun Pharmaceutical Industries Inc. | 1 | $14 |
| Novartis | 1 | $11 |
How this compares
$3,900 in reported general payments places this provider in the 95th percentile of 12,963 general practice providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 513 | $383,916 |
| JanumetSitagliptin Phos/Metformin Hcl | 508 | $319,936 |
| EliquisApixaban | 328 | $202,829 |
| Diclofenac Sodium | 402 | $198,182 |
| Dexlansoprazole DrDexlansoprazole | 663 | $159,955 |
| Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate | 117 | $137,757 |
| FarxigaDapagliflozin Propanediol | 208 | $134,902 |
| JanuviaSitagliptin Phosphate | 162 | $120,259 |
| VascepaIcosapent Ethyl | 294 | $106,531 |
| LinzessLinaclotide | 162 | $98,080 |
| OzempicSemaglutide | 87 | $83,168 |
| Icosapent Ethyl | 398 | $81,949 |
| Metformin Hcl | 1,015 | $77,026 |
| DapagliflozinDapagliflozin Propanediol | 115 | $75,940 |
| JentaduetoLinagliptin/Metformin Hcl | 105 | $62,252 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Jentadueto, Tradjenta | $156 | $505,429732 claims |
| MerckJanumet, Januvia, Janumet Xr | $60 | $462,790720 claims |
| PfizerEliquis | $88 | $202,829328 claims |
| AbbVieLinzess, Namzaric, Creon | $437 | $143,034230 claims |
| AstraZenecaFarxiga | $285 | $134,902208 claims |
| Novo NordiskOzempic, Rybelsus | $65 | $94,00098 claims |
| AmgenProlia | $583 | $54,60932 claims |
| NovartisEntresto | $11 | $49,56078 claims |
| Astellas Pharma US IncMyrbetriq | $210 | $48,174106 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Multaq | $152 | $47,31441 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Dexilant | $49 | $31,85061 claims |
| GSKTrelegy Ellipta | $94 | $20,57024 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 12,963 general practice providers in California.
Other general practice in Glendale
- Marina GoldGlendale$784K
- Hessam AazamiCanoga Park$88.4M
- Frederic MollRedwood City$5.7M
- Nathan LiLancaster$5.2M
- Milton McCollSan Jose$4.9M
- Bruce TorkanLos Angeles$3.8M
- Daniel JohnsonPalm Desert$1.5M
- Bradley ChingUpland$1.4M
- Jared AdamsSan Francisco$862K
- Eric BrassTorrance$755K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.